Testing effectiveness (Phase 2)Study completedNCT00505739What this trial is testingMifepristone for Patients With Endometrial Cancer and LGESSWho this might be right forEndometrial Cancer M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT03348631What this trial is testingTazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerWho this might be right forRecurrent Endometrial Endometrioid AdenocarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian Carcinoma+2 more National Cancer Institute (NCI) 62
Early research (Phase 1)Active Not RecruitingNCT03120624What this trial is testingVSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerWho this might be right forMetastatic Endometrial CarcinomaRecurrent Endometrial AdenocarcinomaRecurrent Endometrial Carcinoma+7 more Mayo Clinic 34
Testing effectiveness (Phase 2)Study completedNCT02684227What this trial is testingEnzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial CancerWho this might be right forRecurrent Endometrial Endometrioid AdenocarcinomaRecurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7+6 more M.D. Anderson Cancer Center 50
Not applicableStudy completedNCT01208467What this trial is testingPrognostic Biomarkers in Patients With Endometrial CancerWho this might be right forEndometrial AdenocarcinomaRecurrent Uterine Corpus CarcinomaStage I Uterine Corpus Cancer+3 more Gynecologic Oncology Group 2,824
Large-scale testing (Phase 3)Active Not RecruitingNCT03914612What this trial is testingTesting the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerWho this might be right forEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more National Cancer Institute (NCI) 813
Large-scale testing (Phase 3)Study completedNCT02598219What this trial is testingEvaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.Who this might be right forNon Endometrioid CarcinomaEndometrioid Carcinoma Centre Oscar Lambret 262
Testing effectiveness (Phase 2)Study completedNCT01210222What this trial is testingTrebananib in Treating Patients With Persistent or Recurrent Endometrial CancerWho this might be right forEndometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+4 more Gynecologic Oncology Group 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03008408What this trial is testingA Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaWho this might be right forRecurrent Endometrial CarcinomaRecurrent Endometrial Endometrioid AdenocarcinomaRefractory Endometrial Carcinoma+10 more M.D. Anderson Cancer Center 90
Early research (Phase 1)Active Not RecruitingNCT04092270What this trial is testingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerWho this might be right forEndometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more National Cancer Institute (NCI) 55
Not applicableActive Not RecruitingNCT04604613What this trial is testingPrediction of Recurrence Among Low Risk Endometrial Cancer PatientsWho this might be right forFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma M.D. Anderson Cancer Center 518
Early research (Phase 1)Study completedNCT01440998What this trial is testingDasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerWho this might be right forEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous Adenocarcinoma+13 more National Cancer Institute (NCI) 18